文献速递临床试验与 GCP真实世界研究与卫生经济

老年人是否停用他汀?一项随机对照试验的研究方案

Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-04-19

SITE研究是一项在法国门诊初级保健机构开展的多中心、开放标签、平行组随机对照试验,纳入75岁及以上、以他汀作为心血管事件一级预防的患者,随访3年。主要目的是评估停用他汀的成本效果,并检验停用他汀在全因死亡率上的非劣效性,计划纳入2430人。

要点

  • 评估75岁及以上一级预防患者停用他汀的成本效果与死亡率非劣效性。
  • 主要临床终点为全因死亡率,非劣效界值为组间死亡率差异5%。
  • 计划纳入2430人,假设3年死亡率为15%,把握度90%。

核心结论

  • SITE研究旨在检验75岁及以上一级预防患者停用他汀在死亡率上是否非劣效于继续他汀,并评估其成本效果。

研究设计与样本

  • SITE研究为正在进行的3年随访、开放标签、多中心、平行组随机对照试验,在法国门诊初级保健诊室开展。
  • 纳入75岁及以上、以他汀作为心血管事件一级预防且签署知情同意书的患者。
  • 随机后停用他汀策略组被指示撤除治疗,对照策略组以常规剂量继续他汀治疗。
  • 计划纳入2430名个体。

关键数值与推荐

  • 主要临床终点为全因死亡率。
  • 假设3年死亡率为15%。
  • 样本量计算以达到90%把握度显示停用他汀的非劣效性,非劣效界值为组间全因死亡率差异的5%。
  • 成本效果通过36个月时每获得一个质量调整生命年(QALY)的增量成本估算,采用法国医疗系统视角。

临床怎么用

  • 该研究方案尚未提供停用他汀对死亡率或成本效果的结果,临床决策应等待试验数据发表。

局限性

  • 原文指出他汀在75岁以上人群一级预防中的疗效证据缺乏,且存在依从性相关事件、药物相互作用和副作用可能影响生活质量。
  • 临床试验数据指导心血管病一级或二级预防的用药启动,但未定义停药时机、安全性或风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk/benefit ratio of using statins for primary prevention of cardiovascular (CV) events in elderly people has not been established. The main objectives of the present study are to assess the cost-effectiveness of statin cessation and to examine the non-inferiority of statin cessation in terms of mortality in patients aged 75 years and over, treated with statins for primary prevention of CV events. METHODS: The "Statins in the elderly" (SITE) study is an ongoing 3-year follow-up, open-label comparative multi-centre, randomized clinical trial that is being conducted in two parallel groups in outpatient primary care offices. Participants meeting the following criteria are included: people aged 75 years and older being treated with statins as primary prevention for CV events, who provide informed consent. After randomization, patients in the statin-cessation strategy are instructed to withdraw their treatment. In the comparison strategy, patients continue their statin treatment at the usual dosage. The cost-effectiveness of the statin-cessation strategy compared to continuing statins will be estimated through the incremental cost per quality-adjusted life years (QALYs) gained at 36 months, from the perspective of the French healthcare system. Overall mortality will be the primary clinical endpoint. We assumed that the mortality rate at 3 years will be 15%. The sample size was computed to achieve 90% power in showing the non-inferiority of statin cessation, assuming a non-inferiority margin of 5% of the between-group difference in overall mortality. In total, the SITE study will include 2430 individuals. DISCUSSION: There is some debate on the value of statins in people over 75 years old, especially for primary prevention of CV events, due to a lack of evidence of their efficacy in this population, potential compliance-related events, drug-drug interactions and side effects that could impair quality of life. Data from clinical trials guide the initiation of medication therapy for primary or secondary prevention of CV disease but do not define the timing, safety, or risks of discontinuing the agents. The SITE study is one of the first to examine whether treatment cessation is a cost-effective and a safe strategy in people of 75 years and over, formerly treated with statins. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02547883. Registered on 11 September 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bonnet F, Bénard A, Poulizac P, et al. Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial. Trials. 2020. PMID: 32307005. doi:10.1186/s13063-020-04259-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。